SCHEMBL475629

SCHEMBL475629

NC(=O)C1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PREP P48147 3/20 0.64
CTRB1 P17538 1/20 0.60
CYP2C19 P33261 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
NPSR1 Q6W5P4 1/20 0.59
KDM1A O60341 1/20 0.59
RCOR1 Q9UKL0 1/20 0.59
SPHK2 Q9NRA0 1/20 0.58
SPHK1 Q9NYA1 1/20 0.58
TSHR P16473 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
KMT2A Q03164 1/20 0.58
KLK7 P49862 1/20 0.58
KLK5 Q9Y337 1/20 0.58
KDM4E B2RXH2 1/20 0.58
LMNA P02545 1/20 0.58
CYP3A4 P08684 1/20 0.58
MAPT P10636 1/20 0.58
CYP2C9 P11712 1/20 0.58
RAB9A P51151 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL809457 1.00 PREP (0.64) PREPCTRB1CYP2C19SMN1; SMN2NPSR1
SCHEMBL1437568 1.00 PREP (0.64) PREPCTRB1CYP2C19SMN1; SMN2NPSR1
SCHEMBL11337356 0.96 PREP (0.60) PREPCTRB1CYP2C19SMN1; SMN2NPSR1
Hydrochloric Acid SCHEMBL27702337 0.95 PREP (0.58) PREPCTRB1CYP2C19SMN1; SMN2NPSR1
SCHEMBL1056316 0.92 SMN1; SMN2 (0.63) PREPCTRB1CYP2C19SMN1; SMN2NPSR1
SCHEMBL1056315 0.92 SMN1; SMN2 (0.63) PREPCTRB1CYP2C19SMN1; SMN2NPSR1
SCHEMBL30011307 0.90 PREP (0.61) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL13209657 0.90 PREP (0.61) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL12139909 0.90 PREP (0.61) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL10173007 0.90 PREP (0.61) PREPCTRB1NPSR1KDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112739343-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2021-04-30 CN disclosed
CN-112533598-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2021-03-19 CN disclosed
CN-111818916-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2020-10-23 CN disclosed
EP-1725548-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS VERTEX PHARMA (US) 2015-01-14 EP disclosed
EP-2399915-B1 Process and intermediates for the preparation of aspartic acetal caspase inhibitors VERTEX PHARMA (US) 2014-12-17 EP disclosed
EP-2399916-B1 Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors VERTEX PHARMA (US) 2014-12-10 EP disclosed
EP-1836201-B2 PYRROLIDINE INHIBITORS OF IAP GENENTECH INC (US) 2013-09-04 EP disclosed
US-8372985-B2 Process of making α-aminooxyketone/α-aminooxyaldehyde and α-hydroxyketone/α-hydroxyaldehyde compounds and a process of making reaction products from cyclic α, β-unsaturated ketone substrates and nitroso substrates JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2013-02-12 US disclosed
US-8372985-B2 Process of making α-aminooxyketone/α-aminooxyaldehyde and α-hydroxyketone/α-hydroxyaldehyde compounds and a process of making reaction products from cyclic α, β-unsaturated ketone substrates and nitroso substrates JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2013-02-12 US disclosed
US-8288371-B2 Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation PHARMACOPEIA, LLC (US) 2012-10-16 US disclosed
WO-2010042892-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2010-04-15 WO disclosed
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-12-24 US disclosed
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-09 US disclosed
US-20090093472-A1 ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION PHARMACOPEIA, INC. (US) 2009-04-09 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed
EP-0195212-B1 Novel peptidase inhibitors MERRELL DOW PHARMA (US) 1993-11-24 EP disclosed
US-4822892-A ANTITUMOR AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1989-04-18 US disclosed
EP-0195212-A2 Novel peptidase inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1986-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 PREP 4027/4885CTRB1 1316/4885CYP2C19 632/4885
US-20090093472-A1 ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION CCR1, CCR4, CCR3 PREP 296/4885CTRB1 1105/4885CYP2C19 2465/4885
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 PREP 130/4885CTRB1 778/4885CYP2C19 4873/4885
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 PREP 130/4885CTRB1 778/4885CYP2C19 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.